Two Sigma Securities’s Bio-Rad Laboratories Class A BIO Stock Holding History

Two Sigma Securities’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-600	Closed	-$208K	–	2991
2024 Q1	$208K	Buy	+600	New	+$197K	﹤0.01%	2308
2022 Q4	–	Sell	-1,300	Closed	-$542K	–	2595
2022 Q3	$542K	Buy	1,300 +300	+30%	+$150K	0.02%	1039
2022 Q2	$495K	Buy	+1,000	New	+$521K	0.02%	923

Other funds holding BIO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's BIO Position: Q1 2026 in Review

Two Sigma Securities sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 1,199 shares — an estimated $363K sold.

Two Sigma Securities first reported a position in BIO in Q3 2022 and held it in 4 quarters. The position peaked at $920K in Q3 2022. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

Two Sigma Securities reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 1,199 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $363K.
Two Sigma Securities first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 4 quarters.
Two Sigma Securities's Bio-Rad Laboratories Class A position peaked at $920K in Q3 2022.
391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.